ChromaDex Co. (NASDAQ:CDXC – Get Rating) insider Robert N. Fried bought 80,000 shares of the stock in a transaction dated Friday, September 30th. The stock was purchased at an average cost of $1.25 per share, for a total transaction of $100,000.00. Following the acquisition, the insider now owns 972,314 shares in the company, valued at approximately $1,215,392.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

ChromaDex Stock Up 7.3 %

Shares of NASDAQ:CDXC opened at $1.32 on Tuesday. ChromaDex Co. has a 12 month low of $1.15 and a 12 month high of $6.98. The company's 50-day moving average price is $1.55 and its two-hundred day moving average price is $1.83. The firm has a market cap of $90.21 million, a P/E ratio of -3.22 and a beta of 1.71.

Get ChromaDex alerts:

ChromaDex (NASDAQ:CDXC – Get Rating) last issued its quarterly earnings data on Wednesday, August 10th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.01). ChromaDex had a negative return on equity of 99.51% and a negative net margin of 41.01%. During the same quarter in the prior year, the business posted ($0.08) EPS. As a group, equities analysts predict that ChromaDex Co. will post -0.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ChromaDex

A number of hedge funds have recently added to or reduced their stakes in CDXC. Cubist Systematic Strategies LLC lifted its position in ChromaDex by 142.3% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 63,286 shares of the company's stock valued at $106,000 after purchasing an additional 37,163 shares during the period. Millennium Management LLC acquired a new position in ChromaDex during the 2nd quarter valued at about $1,275,000. Virtu Financial LLC acquired a new position in ChromaDex during the 2nd quarter valued at about $76,000. Renaissance Technologies LLC lifted its position in ChromaDex by 76.0% during the 2nd quarter. Renaissance Technologies LLC now owns 739,900 shares of the company's stock valued at $1,236,000 after purchasing an additional 319,399 shares during the period. Finally, Tieton Capital Management LLC lifted its position in ChromaDex by 59.9% during the 2nd quarter. Tieton Capital Management LLC now owns 2,285,015 shares of the company's stock valued at $3,816,000 after purchasing an additional 856,273 shares during the period. Institutional investors own 41.83% of the company's stock.

Analyst Upgrades and Downgrades

CDXC has been the topic of several analyst reports. HC Wainwright lowered their target price on shares of ChromaDex from $7.00 to $5.50 and set a "buy" rating on the stock in a report on Monday, August 29th. B. Riley lowered shares of ChromaDex from a "buy" rating to a "neutral" rating and lowered their target price for the stock from $6.00 to $2.40 in a report on Thursday, August 11th. Finally, Oppenheimer lowered shares of ChromaDex from an "outperform" rating to a "market perform" rating in a report on Tuesday, August 16th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $5.48.

ChromaDex Company Profile

(Get Rating)

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.

Further Reading

• Get a free copy of the StockNews.com research report on ChromaDex (CDXC)
• Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
• 3 Stocks Growing Their Businesses for 2023
• China-Based EV Maker BYD Set For Big European, Japanese Expansion
• Is Illumina Still the Gamechanger in Genomics Sequencing?
• Here's What Makes Amazon a Sum-of-All-Parts Commerce Juggernaut

Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.